[go: up one dir, main page]

WO2024034424A1 - Composition pour améliorer la motivation - Google Patents

Composition pour améliorer la motivation Download PDF

Info

Publication number
WO2024034424A1
WO2024034424A1 PCT/JP2023/027669 JP2023027669W WO2024034424A1 WO 2024034424 A1 WO2024034424 A1 WO 2024034424A1 JP 2023027669 W JP2023027669 W JP 2023027669W WO 2024034424 A1 WO2024034424 A1 WO 2024034424A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
molecular weight
guar gum
mass
mannose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2023/027669
Other languages
English (en)
Japanese (ja)
Inventor
綾 安部
誠 小関
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TAIYOKAGAKU CO Ltd
Original Assignee
TAIYOKAGAKU CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TAIYOKAGAKU CO Ltd filed Critical TAIYOKAGAKU CO Ltd
Priority to JP2024540377A priority Critical patent/JPWO2024034424A1/ja
Publication of WO2024034424A1 publication Critical patent/WO2024034424A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/238—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • the present invention relates to a composition for increasing motivation.
  • JP2022-097984A Japanese Patent Application Publication No. 2006-096715
  • Patent Document 1 contains an extract and/or a pulverized product of a plant belonging to the genus Salacia. Since it would be desirable to be able to provide more compositions that increase motivation, there remains room for research.
  • the present invention has been made in view of the above problems, and its purpose is to provide a novel composition for increasing motivation and/or a composition for improving wakefulness upon waking up.
  • the present inventor discovered that a composition containing a specific guar gum decomposition product has an effect of increasing motivation, and basically completed the present invention.
  • the composition for increasing motivation after sleep according to the present invention is a decomposed product of guar gum having an average molecular weight of 1.0 ⁇ 10 3 to 2.0 ⁇ 10 5 and containing 70% by mass or more of substances within the average molecular weight range. and the viscosity of a 1% by mass aqueous solution when measured at 25 ° C.
  • the guar gum decomposition product is contained in the endosperm derived from guar, It is obtained by hydrolyzing galactomannan polysaccharide with a content ratio of galactose and mannose (galactose:mannose) in the range of 1:1.3 to 1:2.1 using microorganism-derived ⁇ -mannanase to reduce the molecular weight. It is characterized by containing at least 70% by mass of dietary fiber as determined by the enzyme-HPLC method.
  • a composition for improving wakefulness when waking up according to another invention has an average molecular weight of 1.0 ⁇ 10 3 to 2.0 ⁇ 10 5 and contains 70% by mass or more of guar gum within the range of average molecular weight.
  • the guar gum decomposition product is a substance having a viscosity of 50 mPa ⁇ s or less of a 1% by mass aqueous solution when measured at 25°C and 60 rpm using a B-type viscometer, and the guar gum decomposition product is not contained in the guar-derived endosperm.
  • the composition for increasing motivation or the composition for improving wakefulness is intended for healthy people without sleep disorders.
  • food/beverage products or pharmaceuticals containing the composition for increasing motivation or the composition for improving wakefulness of the present invention can be provided.
  • Food and beverages include foods and beverages, such as nutritional supplements, health foods, foods for specified health uses, foods with functional claims, diet foods, comprehensive health foods, supplements, tea drinks, coffee drinks, and juices. Examples include soft drinks, drinks, cooked rice, bread, noodles, dairy products, processed egg products, processed fish and livestock foods, confectionery, fats and oils and processed foods, seasonings, and side dishes.
  • Pharmaceuticals include pharmaceuticals or quasi-drugs, and are preferably oral preparations or enteral preparations, and can be in the form of liquids, tablets, granules, pills, syrups, and the like.
  • a novel composition for increasing motivation and/or a composition for improving wakefulness upon waking up can be provided.
  • VA vitality
  • Guar gum is a water-soluble natural polysaccharide obtained from the endosperm (more precisely, cotyledons) of guar beans, and it has two molecules of mannose linked in a linear chain and one molecule of galactose as a side chain. It is a polysaccharide and has an average molecular weight of about 2.0 ⁇ 10 5 to 3.0 ⁇ 10 5 . Guar gum is known to have physiological effects such as suppressing blood sugar levels, lowering cholesterol, and improving bowel movements.
  • the guar gum decomposition product is made from beans derived from guar (scientific name: Cyanopsis tetragoloba), an annual legume that is edible in India, Pakistan, etc., and is produced by hydrolyzing the galactomannan polysaccharide contained in the endosperm. It means water-soluble dietary fiber obtained by reducing the molecular weight.
  • Methods for hydrolyzing guar gum include, but are not particularly limited to, enzymatic decomposition methods, acid decomposition methods, etc., but enzymatic decomposition methods are preferred from the viewpoint of easy adjustment of the molecular weight of decomposed products.
  • the enzyme used in the enzymatic decomposition method is not particularly limited as long as it is an enzyme that hydrolyzes linear mannose chains, but it is preferable to use ⁇ -mannanase derived from bacteria of the genus Aspergillus or Rhizopus.
  • the average molecular weight distribution of the guar gum decomposition product has an upper limit of 2.0 ⁇ 10 5 or less, preferably 1.0 ⁇ 10 5 or less, and more preferably 2.5 ⁇ 10 4 or less.
  • the lower limit of the average molecular weight distribution of the guar gum decomposition product is 1.0 ⁇ 10 2 or more, preferably 2.0 ⁇ 10 3 or more.
  • the method for measuring molecular weight distribution is not particularly limited ; There are methods using filtration chromatography, etc.
  • the guar gum decomposition product of the present invention contains 70% by mass or more, preferably 80% by mass or more of molecules within the above average molecular weight range.
  • Galactose is a type of monosaccharide classified as aldohexose, and has a molecular formula of C 6 H 12 O 6 and a molecular weight of 180 (both are the same as glucose).
  • the configuration is that -OH at the 2nd position (second from the top in Fischer projection) and the 5th position are in the same direction, and the 3rd and 4th positions are in opposite directions, and the configuration at the 5th position of D-galactose is D-glycer.
  • Mannose is a type of monosaccharide classified as an aldohexose, and has a molecular formula of C 6 H 12 O 6 and a molecular weight of 180 (both are the same as glucose).
  • the steric configuration is that -OH at the 2nd and 3rd positions are in the same direction, and the 4th and 5th positions are in opposite directions, and the steric configuration at the 5th position of D-mannose is the same as that of D-glyceraldehyde.
  • Mannose is poorly metabolized in humans, and when ingested orally, it hardly enters the glycolytic system.
  • “Motivation” is an expression that means a positive feeling or desire to do something or accomplish something on one's own. It is recognized that motivation is brought about by dopamine, which is secreted by the brain. It is known that people lose motivation due to irregular lifestyle habits, accumulated fatigue, lack of sleep, etc.
  • the composition for increasing motivation of the present invention can be orally ingested as it is or mixed with food, drinks, etc.
  • the dosage of the composition for increasing motivation when ingested orally is not particularly limited, but is 0.5 g to 70 g (preferably 3 g to 30 g, more preferably 6 g to 18 g) per adult per day.
  • guar gum decomposition product (PHGG)>
  • Example 1 After adjusting the pH to 4.5 by adding 0.1N hydrochloric acid to 900 g of water, 0.2 g of commercially available ⁇ -mannanase derived from Aspergillus bacteria and 100 g of guar gum powder were added and mixed. This mixture was allowed to react at 40°C to 45°C for 24 hours. After the reaction, the enzyme was inactivated by heating at 90°C for 15 minutes. The reaction solution was filtered and separated by suction filtration, insoluble materials were removed, and the resulting clear solution was concentrated under reduced pressure (Yamato evaporator). The solid content was 20% by mass.
  • the viscosity of the 1% by mass aqueous solution was measured using a B-type viscometer at 25° C. and 60 rpm, and found to be 8 mPa ⁇ s.
  • the content ratio of galactose and mannose was measured and found to be 1:1.7.
  • the dietary fiber content was measured by enzyme-HPLC method and was found to be 90% by mass.
  • Example 2 After adjusting the pH to 3 by adding 0.1N hydrochloric acid to 900 g of water, 0.15 g of commercially available ⁇ -mannanase derived from Aspergillus bacteria and 100 g of guar gum powder were added and mixed. This mixture was allowed to react at 40°C to 45°C for 24 hours. After the reaction, the enzyme was inactivated by heating at 90°C for 15 minutes. The reaction solution was filtered and separated by suction filtration, insoluble materials were removed, and the resulting clear solution was concentrated under reduced pressure (Yamato evaporator). The solid content was 20% by mass.
  • a guar gum decomposition product was dried using a spray dryer (manufactured by Okawara Kakoki Co., Ltd.) to obtain 68 g of a guar gum decomposition product as a powder.
  • the average molecular weight of the guar gum decomposition product was determined in the same manner as in Example 1, and was found to be approximately 2.5 ⁇ 10 4 . From the results of the HPLC chart, it was found that 80% by mass or more contained molecules having a molecular weight of 1.0 ⁇ 10 3 to 2.0 ⁇ 10 4 . Further, the viscosity of the 1% by mass aqueous solution was measured using a B-type viscometer at 25° C. and 60 rpm, and found to be 10 mPa ⁇ s. The content ratio of galactose and mannose (galactose:mannose) was measured and found to be 1:1.8. The dietary fiber content was measured by enzyme-HPLC method and was 89% by mass.
  • Example 3 After adjusting the pH to 4 by adding 0.1N hydrochloric acid to 900 g of water, 0.25 g of commercially available ⁇ -mannanase derived from Aspergillus bacteria and 100 g of guar gum powder were added and mixed. This mixture was allowed to react at 50°C to 55°C for 12 hours. After the reaction, the enzyme was inactivated by heating at 90°C for 15 minutes. The reaction solution was filtered and separated by suction filtration, insoluble materials were removed, and the resulting clear solution was concentrated under reduced pressure (Yamato evaporator). The solid content was 20% by mass.
  • Example 4 A guar gum decomposition product was prepared according to the description in Examples (page 4, line 3 to page 4, line 10) of JP-A-5-117156. The average molecular weight was determined according to Example 1 and was found to be 5.5 ⁇ 10 3 .
  • ⁇ Test method 1> A placebo-controlled, double-blind, randomized, parallel-group comparative study was conducted to examine the effects of PHGG on wake-up sensations and motivation. Sixty healthy subjects aged 30 to 50 were divided into 3 groups of 20 each, and each group was given a placebo powdered food, 3 g/day of PHGG in Example 1, and 5 g/day of PHGG daily for 8 weeks. A questionnaire survey regarding sleep and motivation was conducted at weeks 0, 4, and 8, and the total sleep health risk score, feeling refreshed upon waking up, fatigue upon waking up, and motivation scores for work and study were calculated. did.
  • Sleep health risk total score is the 1st factor (related to sleep maintenance disorder) and 2nd factor for each evaluation item of the Sleep Health Risk Index (SHRI) (Non-patent Document 1). It was calculated from the sum of the scores for each factor: factor 3 (related to parasomnia symptoms), factor 3 (related to sleep apnea), factor 4 (related to difficulty getting up), and factor 5 (related to difficulty falling asleep). A higher score indicates a higher risk for overall sleep health. Scores regarding the feeling and motivation upon waking up were scored between 0 (worst) and 10 (best) using a VAS (visual analog scale) (Non-Patent Document 2). The higher the score, the better.
  • VAS visual analog scale
  • Table 1 and Figure 1 summarize the total sleep health risk score
  • Table 2 and Figures 2 to 4 summarize the VAS questionnaire benefits regarding feeling refreshed when waking up, feeling tired when waking up, and motivation for work and study. The results are shown below. Since there were cases of dropouts in all groups, data analysis was performed on 19 patients in the placebo group, 14 patients in the PHGG (3g intake group), and 17 patients in the PHGG (5g intake group).
  • Patent Document 2 discloses that dietary fiber has the effect of improving sleep and health. According to the test in this document, cookies containing dietary fiber (gum arabic) have been shown to improve the total sleep health risk score (paragraph 0021). In response to this disclosed technology, the present inventor conducted a test on dietary fiber containing a specific low-molecular-weight guar gum in the hope that it would have a sleep-improving effect. However, surprisingly, for the composition of the present invention, there was no significant difference in sleep health risk total score between the placebo group and the PHGG group (both 3g and 5g) (Table 1 and Figure 1). For this reason, we had no choice but to abandon the use of the PHGG of the present invention for comprehensive sleep improvement.
  • ⁇ Test method 2> A placebo-controlled, double-blind, randomized, parallel-group comparative study was conducted in healthy elderly subjects to verify the effects of PHGG on wakefulness, sleep onset and maintenance, dreaminess, recovery from fatigue, and sleep duration. The subjects were healthy male and female subjects over the age of 60. Of the 91 screening cases, 66 healthy people who were not included in the exclusion criteria were targeted.
  • Exclusion criteria include a history of malignant tumor or heart disease, people wearing pacemakers, people treating arrhythmia, liver damage, kidney damage, diabetes, dyslipidemia, hypertension, etc., regular users of medicines or supplements, people with allergies, Those who have a habit of exercising (more than 2 times/week, 30 minutes or more/time, more than 1 year), those infected with the new coronavirus, participants in other clinical trials within 28 days before the date of consent form, and others are responsible. Those who were judged to be unsuitable by a doctor. The 66 people were randomly divided into two groups, one group was the test food group (33 people) and the other was the placebo group (33 people).
  • the subject group was given 5 g/day of the PHGG of Example 1, and the placebo group was given 5 g/day of the powdered placebo food with breakfast every day for 12 weeks. There were 3 participants who dropped out in the test group and 2 participants in the placebo group, so data from 30 and 31 participants were analyzed, respectively.
  • POMS2 is a test that can quickly assess not only relatively long-lasting emotional states, but also fluctuating and transient emotions.It has seven factors: anger-hostility (AH), confusion-embarrassment (CB ), ⁇ Depression-Depression (DD),'' ⁇ Fatigue-Apathy (FI),'' ⁇ Tension-Anxiety (TA),'' ⁇ Vibrance-Vitality (VA),'' ⁇ Friendliness (F),'' and overall Including TMD as an indicator of mood state.
  • AH anger-hostility
  • CB confusion-embarrassment
  • DD ⁇ Depression-Depression
  • FI ⁇ Fatigue-Apathy
  • TA ⁇ Tension-Anxiety
  • VA ⁇ Vibrance-Vitality
  • F ⁇ Friendliness
  • a score below 30 is “very low”
  • a score between 30 and 39 is “low”
  • a score between 40 and 59 is “average”
  • a score between 0 and 69 is “high”
  • a score above 70 is “very high”. ”
  • the lower the value of TMD, AH, CB, DD, FI, and TA the better
  • the higher the value of VA, F the better.
  • OSA-MA is a test that evaluates drowsiness upon waking, sleep onset and maintenance, dreaminess, recovery from fatigue, and sleep duration, and was conducted at home upon waking for each of the 3 days before the test (on the day, the day before, and the day before). . The average value over 3 days was used as the measured value.
  • Table 5 shows the mean value (Mean), standard deviation (SD), median value (Med), minimum value (Min), maximum value (Max), group difference ( ⁇ ), and standard deviation of each OSA-MA score.
  • Error (SE) minimum value of 95% confidence interval (95%CI+), maximum value of 95% confidence interval (95%CI+), and statistical analysis results are shown.
  • OSA-MA is a psychological scale that evaluates the internal state of sleep upon awakening, and higher values indicate better condition. Among the OSA-MA scores, it was confirmed that ⁇ drowsiness upon waking up'' was affected by the intake of guar gum decomposition products.
  • a novel composition for increasing motivation and/or a composition for improving wakefulness upon waking up could be provided.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

[Problème] L'objet de la présente invention est de fournir une nouvelle composition pour améliorer la motivation et/ou une composition pour améliorer l'état de veille lors de la sortie du lit. [Solution] Le problème mentionné ci-dessus est résolu par une composition pour améliorer la motivation après le sommeil ou une composition pour améliorer l'éveil lors de la sortie du lit, la composition étant caractérisée en ce qu'elle est un produit de décomposition de gomme de guar qui a un poids moléculaire moyen de 1,0×103 à 2,0×105 et contient une quantité supérieure ou égale à 70 % en masse de substances dans une plage de poids moléculaire moyenne, la viscosité d'une solution aqueuse à 1 % en masse du produit de décomposition de gomme de guar étant inférieure ou égale à 50 mPa·s lorsqu'elle est mesurée à 25 °C et 60 tours par min au moyen d'un viscosimètre de type B, le produit de décomposition de gomme de guar étant obtenu par hydrolyse de polysaccharides de galactomannane, qui sont contenus dans l'endosperme dérivé de guar et pour lesquels le rapport de teneur (galactose:mannose) de galactose et de mannose est dans la plage de 1:1,3 à 1:2,1, au moyen de la β-mannanase dérivée de micro-organismes, puis la réduction du poids moléculaire, et la composition contenant au moins 70 % en masse de teneur en fibres alimentaires établie par HPLC enzymatique.
PCT/JP2023/027669 2022-08-08 2023-07-27 Composition pour améliorer la motivation Ceased WO2024034424A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024540377A JPWO2024034424A1 (fr) 2022-08-08 2023-07-27

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022126026 2022-08-08
JP2022-126026 2022-08-08

Publications (1)

Publication Number Publication Date
WO2024034424A1 true WO2024034424A1 (fr) 2024-02-15

Family

ID=89851597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/027669 Ceased WO2024034424A1 (fr) 2022-08-08 2023-07-27 Composition pour améliorer la motivation

Country Status (2)

Country Link
JP (1) JPWO2024034424A1 (fr)
WO (1) WO2024034424A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02248401A (ja) * 1989-03-22 1990-10-04 Godo Shiyusei Kk 低分子グアーガム、その製造法およびそれを含有する飲食品
JPH05117156A (ja) * 1991-10-23 1993-05-14 Res Dev Corp Of Japan 過血糖に付随する疾患の予防および治療剤
JP2012162482A (ja) * 2011-02-07 2012-08-30 Taiyo Kagaku Co Ltd 遺伝子発現促進剤
JP2012162483A (ja) * 2011-02-07 2012-08-30 Taiyo Kagaku Co Ltd ステロール−ｏ−アシルトランスフェラーゼ抑制剤
CN109364097A (zh) * 2018-11-05 2019-02-22 福州大学 瓜尔豆胶在制备抗抑郁症药物及保健品中的应用
JP2022111399A (ja) * 2021-01-20 2022-08-01 太陽化学株式会社 ユビキチンリガーゼ阻害組成物、及びこれを含有しガンによって誘導されたカヘキシアを改善するための予防及び／又は治療用組成物
WO2023281985A1 (fr) * 2021-07-09 2023-01-12 太陽化学株式会社 Composition pour augmenter la masse musculaire
WO2023063033A1 (fr) * 2021-10-12 2023-04-20 太陽化学株式会社 Composition d'inhibition de l'obésité sarcopénique, et composition prophylactique et/ou thérapeutique contenant celle-ci pour atténuation de l'obésité sarcopénique induite par le diabète

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02248401A (ja) * 1989-03-22 1990-10-04 Godo Shiyusei Kk 低分子グアーガム、その製造法およびそれを含有する飲食品
JPH05117156A (ja) * 1991-10-23 1993-05-14 Res Dev Corp Of Japan 過血糖に付随する疾患の予防および治療剤
JP2012162482A (ja) * 2011-02-07 2012-08-30 Taiyo Kagaku Co Ltd 遺伝子発現促進剤
JP2012162483A (ja) * 2011-02-07 2012-08-30 Taiyo Kagaku Co Ltd ステロール−ｏ−アシルトランスフェラーゼ抑制剤
CN109364097A (zh) * 2018-11-05 2019-02-22 福州大学 瓜尔豆胶在制备抗抑郁症药物及保健品中的应用
JP2022111399A (ja) * 2021-01-20 2022-08-01 太陽化学株式会社 ユビキチンリガーゼ阻害組成物、及びこれを含有しガンによって誘導されたカヘキシアを改善するための予防及び／又は治療用組成物
WO2023281985A1 (fr) * 2021-07-09 2023-01-12 太陽化学株式会社 Composition pour augmenter la masse musculaire
WO2023063033A1 (fr) * 2021-10-12 2023-04-20 太陽化学株式会社 Composition d'inhibition de l'obésité sarcopénique, et composition prophylactique et/ou thérapeutique contenant celle-ci pour atténuation de l'obésité sarcopénique induite par le diabète

Also Published As

Publication number Publication date
JPWO2024034424A1 (fr) 2024-02-15

Similar Documents

Publication Publication Date Title
US20180104299A1 (en) Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity
JP6254937B2 (ja) 成人対象における認知及び気分に対する植物ポリサッカライドの急性効果
JPWO2009145363A1 (ja) ワスレグサ属植物の熱水抽出物を含む抗うつ様作用又は睡眠改善による疲労回復作用を有する組成物
CN103975993B (zh) 一种2型糖尿病患者可食用的含蔗糖的夹馅麻花及其制作方法
JP6991092B2 (ja) 睡眠の質改善剤
CN104321054A (zh) 睡眠质量改善剂
CN107496469A (zh) 睡眠质量改善剂
US20230124668A1 (en) Psychological fatigue preventer or improver
CN107624068B (zh) 包含肉桂醛和锌的组合物及此类组合物的使用方法
JP2006028051A (ja) 起床時疲労感改善剤、起床時疲労感改善用組成物、及びこれらを含む起床時疲労感改善用飲食物
JP2013075874A (ja) 血糖代謝改善剤
JP6947495B2 (ja) Ｇａｂａを有効成分とする活気および／または活力向上剤
JP4669077B1 (ja) アスパラガス擬葉を有効成分とする自律神経調整剤
CN106470691B (zh) 包含肉桂醛和锌的组合物及此类组合物的使用方法
JP7305595B2 (ja) 精神性疲労、意欲低下または眠気の改善剤
WO2024034424A1 (fr) Composition pour améliorer la motivation
JP2019127439A (ja) 桑葉を含むサプリメント
JP2019006699A (ja) 軽度認知障害改善用の組成物
TWI664975B (zh) 用於調控tph1基因、ddc基因及／或aanat基因表現的香蕉皮萃取物及其應用
US12409202B2 (en) Autonomic nerve regulator and cognitive function improver
US20190388491A1 (en) Anti-fatigue food composition and anti-fatigue agent
JP6427638B1 (ja) バチルスズブチリスの発酵培養液を有効成分として含む睡眠障害の予防、改善又は治療用組成物
JP2025093689A (ja) 認知機能低減抑制剤
CN108260816A (zh) 一种青稞苗保健食品及其制备方法
KR20240092706A (ko) 수면 촉진 및 개선을 위한 젤리와 그 제조 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23852398

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2024540377

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23852398

Country of ref document: EP

Kind code of ref document: A1